Treatment with vigabatrin carries the risk of permanent vision loss. The Food and Drug Administration (FDA) has expanded the approval of Sabril® (vigabatrin; Lundbeck) to include treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback